DocGo (DCGO) insider James Travers granted 150,000 RSUs and reports holdings

Rhea-AI Filing Summary

DocGo Inc. director James M. Travers reported a new equity award from the company. On December 12, 2025, he was granted 150,000 restricted stock units (RSUs) of DocGo common stock under the issuer’s 2021 Stock Incentive Plan at a price of $0 per unit.

Each RSU represents the right to receive one share of common stock upon vesting on December 12, 2026, subject to the plan’s terms. Following this grant, Travers beneficially owns 240,999 shares of DocGo stock directly and 391,028 shares indirectly through Travers Holdings LLC, over which he and Susan D. Travers share voting and dispositive power while each disclaiming beneficial ownership of those securities except to the extent of any pecuniary interest.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider TRAVERS JAMES M

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	150,000	$0.00	--
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 240,999 shares (Direct); Common Stock — 391,028 shares (Indirect, By Travers Holdings LLC)

Footnotes (1)

1. Represents restricted stock units ("RSUs") granted pursuant to the Issuer's 2021 Stock Incentive Plan (the "Plan") that will vest on December 12, 2026, subject to the terms of the Plan. Each RSU represents the right to receive, upon vesting, one share of Common Stock, subject to the terms of the Plan. Securities are held by Travers Holdings LLC. Mr. Travers and Susan D. Travers are the managers of Travers Holdings and have shared voting and dispositive power over the securities of Issuer held by Travers Holdings LLC. Mr. Travers and Susan D. Travers each disclaim beneficial ownership of these securities except to the extent of any pecuniary interest therein.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

TRAVERS JAMES M

(Last) (First) (Middle)

C/O DOCGO INC.

685 THIRD AVENUE, 9TH FLOOR

(Street)

NEW YORK NY 10017

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
DocGo Inc. [ DCGO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
12/12/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/12/2025		A		150,000(1)	A	$0	240,999	D
Common Stock								391,028	I	By Travers Holdings LLC(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents restricted stock units ("RSUs") granted pursuant to the Issuer's 2021 Stock Incentive Plan (the "Plan") that will vest on December 12, 2026, subject to the terms of the Plan. Each RSU represents the right to receive, upon vesting, one share of Common Stock, subject to the terms of the Plan.

2. Securities are held by Travers Holdings LLC. Mr. Travers and Susan D. Travers are the managers of Travers Holdings and have shared voting and dispositive power over the securities of Issuer held by Travers Holdings LLC. Mr. Travers and Susan D. Travers each disclaim beneficial ownership of these securities except to the extent of any pecuniary interest therein.

Remarks:

	/s/ Jerilyn Laskie, as Attorney-in-Fact for James M. Travers	12/16/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did DocGo (DCGO) report for James M. Travers?

DocGo (DCGO) reported that director James M. Travers was granted 150,000 restricted stock units (RSUs) of DocGo common stock on December 12, 2025 at a price of $0 per unit under the 2021 Stock Incentive Plan.

What are the terms of the 150,000 RSUs reported by DocGo (DCGO)?

The 150,000 RSUs granted to James M. Travers were issued under DocGo’s 2021 Stock Incentive Plan. Each RSU represents the right to receive one share of common stock upon vesting, which is scheduled for December 12, 2026, subject to the plan’s terms.

How many DocGo (DCGO) shares does James M. Travers beneficially own after this transaction?

After the reported grant, James M. Travers beneficially owns 240,999 shares of DocGo common stock directly and 391,028 shares indirectly through Travers Holdings LLC.

Who holds the indirect DocGo (DCGO) shares associated with James M. Travers?

The indirect holdings of 391,028 DocGo shares are held by Travers Holdings LLC. James M. Travers and Susan D. Travers are the managers of this entity and share voting and dispositive power, while each disclaims beneficial ownership except to the extent of any pecuniary interest.

When do the newly granted DocGo (DCGO) RSUs to James M. Travers vest?

The 150,000 RSUs granted to James M. Travers are scheduled to vest on December 12, 2026, in accordance with the terms of DocGo’s 2021 Stock Incentive Plan.